

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

Sheet	1	of	1
-------	---	----	---

**Complete if Known**

<b>Application Number</b>	10/736,289
<b>Filing Date</b>	December 12, 2003
<b>First Named Inventor</b>	Wenge Zhong
<b>Art Unit</b>	4614/625
<b>Examiner Name</b>	TBA ZNDALIS
<b>Attorney Docket Number</b>	006539.00001

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner  
Signature**

Linda Davis


Date Considered

8/29/2005

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

***If you need assistance in completing the form, call 1-800-PTO-9189 and select option 2.***



Sheet 1 Of 1

Modified Form PTO-1449

Atty. Docket No.

A-830

Serial No.

10/736,289

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

Applicant

Zhong et al.

Filing Date

December 12, 2003

Group

~~1614~~ 1625**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
gnd	A1	US 3,074,954	01/22/1963	Justus Kenneth Landquist			
gnd	A2	US 5,643,932	07/01/1997	Chihiro et al.			
gnd	A3	US RE37,556 E	02/19/2002	Chihiro et al.			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
gnd	B1	EP 0 154 190 A1	11 Sep 1985	Europe				X

**OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)**

gnd	C1	Catania et al., "Expression and Localization of Cyclin-Dependent Kinase 5 in Apoptotic Human Glioma Cells", Neuro-Oncology, 3:89-98 (2001).
	C2	Chuiguk et al., The Formation of a Condensed Pyridinium Ring During the Reaction of Protonated Cyano- and Nitromethylazoles with 1,3-Diketones", Ukrainskii Khimicheskii Zhurnal, 46(12):1306-1310 (1980).
	C3	Erian et al., "Hydrazones in Heterocyclic Synthesis; Synthesis of 1,3,4-Thiadiazole Derivatives", Phosphorus, Sulfur, and Silicon, 133:127-139 (1998).
	C4	Maccioni et al., "The Protein Kinase Cdk5: Structural Aspects, Roles in Neurogenesis and Involvement in Alzheimer's Pathology", European Journal of Biochemistry, 268:1518-1527 (2001).
	C5	Michael et al., "2-Oxo-3-Cyano Benzo [b] Quinoline. Part II. Some Reactions on 3-Methylketone Derivative", Egyptian Journal of Chemistry, 31(1):117-124 (1988).
	C6	Noguchi et al., "Involvement of Cyclins in Cell Proliferation and Their Clinical Implications in Soft Tissue Smooth Muscle Tumors", American Journal of Pathology, 156(6):2135-2147 (2000).
	C7	Paglini et al., "The Role of the Cdk5-p35 Kinase in Neuronal Development", European Journal of Biochemistry, 268:1528-1533 (2001).
	C8	Schafer et al., "Zur Chemie des 4-Phenyl-thiazolyl-(2)-acetonitrils", Journal f. prakt. Chemie, 316(4):684-692 (1974).
✓	C9	Senderowicz et al., "Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators", Journal of the National Cancer Institute, 92(5): 376-387 (2000).
gnd	C10	Zayed et al., "Studies with Polyfunctionally Substituted Heteroaromatics: The Reactivity of Alkylazoles Towards Electrophilic Reagents", Phosphorus, Sulfur, and Silicon, 102:51-57 (1995).

EXAMINER:

Linda W. Davis

Date Considered:

8/29/2005

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.